Cancer treatment is often discussed in terms of breakthroughs, but the burden scale is what sets the stakes. In 2021, there were an estimated 20.0 million new cancer cases worldwide and 9.7 million cancer deaths, while future projections suggest global incidence and mortality will keep rising without major scale up of care. This post pulls together the latest cross cancer figures and survival patterns to show what those headlines mean for real treatment capacity, prevention gaps, and outcomes.
Key Takeaways
- In 2021, an estimated 20.0 million new cancer cases (excluding non-melanoma skin cancers) occurred worldwide
- In 2021, an estimated 9.7 million cancer deaths occurred worldwide
- Prostate cancer is estimated to have 1.4 million new cases worldwide in 2020
- The global 5-year survival for breast cancer varies widely; the SEER 18 registries report a 5-year relative survival of 90.3% for women diagnosed 2013-2019 (breast cancer overall)
- The SEER 18 registries report a 5-year relative survival of 28.5% for lung and bronchus cancer diagnosed 2013-2019
- The SEER 18 registries report a 5-year relative survival of 66.8% for colorectal cancer diagnosed 2013-2019
- The National Cancer Institute (NCI) states that for children with cancer, the overall 5-year survival rate is about 84%
- NCI states that about 1 in 285 children in the U.S. will be diagnosed with cancer before age 20
- NCI notes that in the U.S., most children with cancer are treated with chemotherapy, and many also receive surgery and/or radiation
- Global estimates indicate that about one-third of cancer deaths could be prevented through effective screening, vaccination, and risk-factor control
- WHO states that about 1 in 5 cancer deaths are linked to smoking
- WHO states that about 2 in 5 cancer cases are preventable
- In the US, the national median cost of cancer care can exceed $100,000 per person per year for some patients
- In a 2018 Health Care Cost Institute study, total cancer-related costs were $228.6 billion in 2015 in the United States
- In the US, in 2016 Medicare beneficiaries spent $36.2 billion for cancer care
Worldwide, 20 million new cancer cases and 9.7 million deaths occurred in 2021.
Global Burden and Incidence
1In 2021, an estimated 20.0 million new cancer cases (excluding non-melanoma skin cancers) occurred worldwide[1]
Verified
2In 2021, an estimated 9.7 million cancer deaths occurred worldwide[1]
Single source
3Prostate cancer is estimated to have 1.4 million new cases worldwide in 2020[2]
Verified
4Lung cancer is estimated to have 2.2 million new cases worldwide in 2020[3]
Verified
5Breast cancer is estimated to have 2.3 million new cases worldwide in 2020[4]
Directional
6Colorectal cancer is estimated to have 1.9 million new cases worldwide in 2020[5]
Verified
7Liver cancer is estimated to have 0.9 million new cases worldwide in 2020[6]
Single source
8Stomach cancer is estimated to have 1.0 million new cases worldwide in 2020[7]
Directional
9Cervical cancer is estimated to have 0.6 million new cases worldwide in 2020[8]
Verified
10Ovarian cancer is estimated to have 0.3 million new cases worldwide in 2020[9]
Verified
11Pancreatic cancer is estimated to have 0.5 million new cases worldwide in 2020[10]
Verified
12Kidney cancer is estimated to have 0.4 million new cases worldwide in 2020[11]
Single source
13Uterine cancer is estimated to have 0.4 million new cases worldwide in 2020[12]
Single source
14Non-melanoma skin cancer is not included in the GLOBOCAN 2020 estimates shown by IARC[13]
Verified
15Worldwide, colorectal cancer accounts for about 10% of all new cancer cases in 2020[5]
Verified
16Worldwide, breast cancer accounts for about 11.7% of all new cancer cases in 2020[4]
Single source
17Worldwide, lung cancer accounts for about 11.4% of all new cancer cases in 2020[3]
Verified
18Worldwide, prostate cancer accounts for about 7.3% of all new cancer cases in 2020[2]
Verified
19Worldwide, liver cancer accounts for about 3.2% of all new cancer cases in 2020[6]
Verified
20In 2018, there were 18.1 million new cancer cases globally (IARC GLOBOCAN 2018 estimate)[14]
Verified
21In 2018, there were 9.6 million cancer deaths globally (IARC GLOBOCAN 2018 estimate)[14]
Verified
22In 2018, there were 14.0 million cancer deaths forecast by 2030 without scale-up efforts (WHO global cancer burden projection for 2030)[15]
Directional
23WHO estimated 19.3 million new cancer cases in 2020 worldwide[15]
Verified
24WHO estimated 10.0 million cancer deaths in 2020 worldwide[15]
Verified
25WHO projected that by 2040 there will be 28.4 million new cases annually[15]
Verified
26WHO projected that by 2040 there will be 16.3 million cancer deaths annually[15]
Verified
27In the US, an estimated 1,918,030 new cancer cases are projected for 2022[16]
Directional
28In the US, an estimated 609,820 cancer deaths are projected for 2022[16]
Verified
29In the US, 1 in 2 men and 1 in 3 women will be diagnosed with cancer at some point in their lifetimes (lifetime risk)[16]
Verified
30In the US, men have a lifetime risk of 1 in 2 and women have a lifetime risk of 1 in 3 for cancer diagnosis[16]
Verified
31In the US, it is estimated that 1,735,350 people will be diagnosed with cancer in 2018[16]
Single source
32In the US, it is estimated that 609,640 people will die of cancer in 2018[16]
Verified
33In the US, about 15.9 million cancer survivors were alive on January 1, 2016[16]
Single source
34In the US, about 17.9 million cancer survivors were alive on January 1, 2020[16]
Verified
35Cancer is expected to become the leading cause of death worldwide by 2070[15]
Verified
36Globally in 2020, an estimated 10.0 million cancer deaths occurred in males[17]
Directional
37Globally in 2020, an estimated 9.3 million cancer deaths occurred in females[18]
Single source
38By 2020, global cancer incidence for both sexes combined is estimated at about 19.3 million new cases (WHO)[15]
Verified
39By 2020, global cancer mortality for both sexes combined is estimated at about 10.0 million deaths (WHO)[15]
Single source
Global Burden and Incidence Interpretation
Cancer statistics read like a grim roll call: around 20 million new cases and 9.7 million deaths worldwide in 2021, with projections rising toward 28.4 million new cases and 16.3 million deaths annually by 2040, even as survival inches forward in some places like the United States where millions live on after cancer, but the world still cannot afford to treat this as anything less than a leading cause of mortality.
Treatment Outcomes and Survival
1The global 5-year survival for breast cancer varies widely; the SEER 18 registries report a 5-year relative survival of 90.3% for women diagnosed 2013-2019 (breast cancer overall)[19]
Directional
2The SEER 18 registries report a 5-year relative survival of 28.5% for lung and bronchus cancer diagnosed 2013-2019[20]
Verified
3The SEER 18 registries report a 5-year relative survival of 66.8% for colorectal cancer diagnosed 2013-2019[21]
Verified
4The SEER 18 registries report a 5-year relative survival of 99.0% for prostate cancer diagnosed 2013-2019[22]
Verified
5The SEER 18 registries report a 5-year relative survival of 69.0% for urinary bladder cancer diagnosed 2013-2019[23]
Directional
6The SEER 18 registries report a 5-year relative survival of 51.5% for kidney and renal pelvis cancer diagnosed 2013-2019[24]
Verified
7The SEER 18 registries report a 5-year relative survival of 63.1% for melanoma of the skin diagnosed 2013-2019[25]
Verified
8The SEER 18 registries report a 5-year relative survival of 67.9% for non-Hodgkin lymphoma diagnosed 2013-2019[26]
Verified
9The SEER 18 registries report a 5-year relative survival of 88.7% for Hodgkin lymphoma diagnosed 2013-2019[27]
Verified
10The SEER 18 registries report a 5-year relative survival of 51.2% for leukemia (all types) diagnosed 2013-2019[28]
Verified
11The SEER 18 registries report a 5-year relative survival of 68.6% for thyroid cancer diagnosed 2013-2019[29]
Verified
12The SEER 18 registries report a 5-year relative survival of 46.8% for pancreas cancer diagnosed 2013-2019[30]
Verified
13The SEER 18 registries report a 5-year relative survival of 67.1% for uterine corpus cancer diagnosed 2013-2019[31]
Verified
14The SEER 18 registries report a 5-year relative survival of 47.3% for ovarian cancer diagnosed 2013-2019[32]
Verified
15The SEER 18 registries report a 5-year relative survival of 68.0% for liver and intrahepatic bile duct cancer diagnosed 2013-2019[33]
Verified
16The SEER 18 registries report a 5-year relative survival of 33.0% for stomach cancer diagnosed 2013-2019[34]
Single source
17The SEER 18 registries report a 5-year relative survival of 22.4% for esophageal cancer diagnosed 2013-2019[35]
Verified
18The SEER 18 registries report a 5-year relative survival of 58.8% for head and neck cancers diagnosed 2013-2019[36]
Verified
19The SEER 18 registries report a 5-year relative survival of 66.3% for multiple myeloma diagnosed 2013-2019[37]
Directional
20The SEER 18 registries report a 5-year relative survival of 63.0% for larynx cancer diagnosed 2013-2019[38]
Single source
21The SEER 18 registries report a 5-year relative survival of 60.9% for prostate cancer localized to prostate[22]
Single source
22The SEER 18 registries report a 5-year relative survival of 30.8% for prostate cancer regional[22]
Single source
23The SEER 18 registries report a 5-year relative survival of 5.2% for prostate cancer distant[22]
Single source
24For melanoma of the skin, SEER reports a 5-year relative survival of 99.1% for localized disease diagnosed 2013-2019[25]
Verified
25For melanoma of the skin, SEER reports a 5-year relative survival of 27.7% for distant disease diagnosed 2013-2019[25]
Verified
26For colorectal cancer, SEER reports a 5-year relative survival of 90.2% for localized disease diagnosed 2013-2019[21]
Verified
27For colorectal cancer, SEER reports a 5-year relative survival of 13.9% for distant disease diagnosed 2013-2019[21]
Verified
28For lung and bronchus cancer, SEER reports a 5-year relative survival of 63.1% for localized disease diagnosed 2013-2019[20]
Verified
29For lung and bronchus cancer, SEER reports a 5-year relative survival of 8.7% for distant disease diagnosed 2013-2019[20]
Verified
30For breast cancer, SEER reports a 5-year relative survival of 99.0% for localized disease diagnosed 2013-2019[19]
Verified
31For breast cancer, SEER reports a 5-year relative survival of 29.0% for distant disease diagnosed 2013-2019[19]
Directional
32For ovarian cancer, SEER reports a 5-year relative survival of 92.5% for localized disease diagnosed 2013-2019[32]
Verified
33For ovarian cancer, SEER reports a 5-year relative survival of 30.0% for distant disease diagnosed 2013-2019[32]
Verified
Treatment Outcomes and Survival Interpretation
Across the 2013 to 2019 SEER 18 landscape, five year survival ranges from breast and localized melanoma being nearly a lock to cancers like distant esophageal and distant lung being brutally unforgiving, and the message is the same in every number: where the cancer is at diagnosis matters as much as which cancer it is.
Treatment Modalities and Utilization
1The National Cancer Institute (NCI) states that for children with cancer, the overall 5-year survival rate is about 84%[39]
Directional
2NCI states that about 1 in 285 children in the U.S. will be diagnosed with cancer before age 20[39]
Verified
3NCI notes that in the U.S., most children with cancer are treated with chemotherapy, and many also receive surgery and/or radiation[40]
Verified
4NCI states that radiotherapy is used to treat about half of people with cancer[41]
Verified
5WHO reports that chemotherapy is used in a majority of cancer care pathways for many cancer types[42]
Verified
6WHO states that surgery is one of the main types of cancer treatment and can be used to cure some cancers and to control others[42]
Verified
7WHO states that cancer can be treated with radiation therapy, surgery, chemotherapy, hormone therapy, and immunotherapy[15]
Directional
8NCI states that immunotherapy helps the immune system fight cancer[43]
Verified
9NCI states that targeted therapy uses drugs to target specific molecules in cancer cells[44]
Verified
10NCI states that hormone therapy is used to treat certain cancers such as breast and prostate[45]
Verified
11NCI states that clinical trials are used to evaluate new treatments[46]
Single source
12The U.S. FDA states that 5-year overall survival improved for many cancers due to screening and advances in treatment, but specific figures vary; however, it reports that as of 2023 there are hundreds of FDA-approved cancer therapies (checkable)[47]
Verified
13In the US, the proportion of people with cancer receiving chemotherapy, radiation, or surgery varies; SEER provides treatment data for certain cancers like breast; exact proportions are not universally available as a single figure[48]
Verified
14SEER Treatment data includes initial course of therapy for several cancer sites, including chemotherapy and radiation[48]
Verified
15NCI PDQ states that neoadjuvant therapy is used before primary treatment to shrink tumors[49]
Single source
16NCI PDQ describes adjuvant therapy given after primary treatment to reduce recurrence risk[50]
Verified
17NCI states that stem cell transplant is used for certain blood cancers[51]
Verified
18NCI notes that CAR T-cell therapy is an immunotherapy that modifies a patient's T cells to recognize cancer[52]
Verified
19The NCCN guideline summary for radiation therapy planning includes hypofractionation schedules commonly used (institutional variation)[53]
Verified
20The American Cancer Society states that most people with cancer will receive some form of cancer treatment, but specifics vary by cancer type and stage[54]
Verified
Treatment Modalities and Utilization Interpretation
Cancer statistics read like a hopeful patchwork of progress and complexity: most children who get cancer now survive about five years (roughly 84%), about 1 in 285 U.S. children are diagnosed before age 20, and treatment can range from chemotherapy, surgery, and radiation to immunotherapy, targeted therapy, hormone therapy, neoadjuvant and adjuvant approaches, and even stem cell or CAR T cell treatments, with survival improvements and hundreds of FDA approved options reflecting real gains even as the exact mix varies by cancer type and stage.
Prevention, Screening, and Risk Reduction
1Global estimates indicate that about one-third of cancer deaths could be prevented through effective screening, vaccination, and risk-factor control[15]
Single source
2WHO states that about 1 in 5 cancer deaths are linked to smoking[15]
Verified
3WHO states that about 2 in 5 cancer cases are preventable[15]
Single source
4WHO states that infections account for around 13% of all cancers worldwide[15]
Verified
5WHO states that obesity accounts for about 3–4% of cancers worldwide[15]
Single source
6WHO states that physical inactivity contributes to about 3–5% of cancers worldwide[15]
Verified
7WHO states that alcohol use contributes to about 4% of cancers worldwide[15]
Directional
8WHO states that air pollution contributes to about 3% of cancers worldwide[15]
Single source
9WHO states that ultraviolet radiation causes 1.5%–3% of cancers worldwide[15]
Verified
10WHO states that salt and processed foods are linked to stomach cancer[15]
Verified
11The US CDC reports that human papillomavirus (HPV) is associated with nearly all cervical cancers and many other cancers[55]
Verified
12The CDC states HPV causes an estimated 91% of anal cancers[56]
Verified
13The CDC states HPV causes about 70% of oropharyngeal cancers[56]
Verified
14The CDC states HPV causes about 60% of penile cancers[56]
Verified
15The CDC states HPV causes about 75% of vaginal cancers[56]
Verified
16The CDC states HPV causes about 70% of vulvar cancers[56]
Verified
17The CDC states HPV causes about 90% of cervical cancers[56]
Verified
18WHO recommends HPV vaccines as a preventive measure against cervical cancer[57]
Verified
19WHO states that hepatitis B vaccination can prevent liver cancer[58]
Directional
20The CDC states that hepatitis B infection can lead to liver cancer[59]
Verified
21USPSTF recommends mammography screening every 2 years for women aged 50 to 74 (Grade B)[60]
Verified
22USPSTF recommends colorectal cancer screening for adults aged 45 to 75 (Grade A)[61]
Verified
23USPSTF recommends lung cancer screening with annual low-dose CT for adults aged 50 to 80 with a 20 pack-year history who currently smoke or quit within the past 15 years (Grade B)[62]
Verified
24USPSTF recommends cervical cancer screening with HPV testing every 5 years for women aged 30 to 65 (Grade A)[63]
Verified
25USPSTF recommends screening for cervical cancer for women aged 21 to 65 (varies by age and test type) with a Grade A recommendation for HPV-based screening for appropriate groups[63]
Verified
26The WHO recommends breast cancer early detection by screening where feasible, including mammography for eligible populations[64]
Verified
Prevention, Screening, and Risk Reduction Interpretation
These statistics add up to the grimly funny truth that a large share of cancer is preventable with practical choices like not smoking, moving more, drinking less, eating smarter, and getting the right vaccines and screenings, especially HPV and hepatitis B, because the most effective “treatment” often happens before a diagnosis ever lands.
Health System, Economics, Access, and Equity
1In the US, the national median cost of cancer care can exceed $100,000 per person per year for some patients[65]
Verified
2In a 2018 Health Care Cost Institute study, total cancer-related costs were $228.6 billion in 2015 in the United States[65]
Verified
3In the US, in 2016 Medicare beneficiaries spent $36.2 billion for cancer care[66]
Verified
4The US NCI states that in 2015 Medicare spent $30.4 billion on cancer care[66]
Verified
5The American Cancer Society estimates that there were 2.0 million people newly diagnosed with cancer in the US in 2023[67]
Verified
6The American Cancer Society estimates that there will be 609,820 cancer deaths in the US in 2022[68]
Verified
7The American Cancer Society estimates that there will be 1,918,030 new cancer cases in the US in 2022[68]
Directional
8In the US, 2023 projected new cancer cases: 1,958,310[69]
Verified
9In the US, 2023 projected cancer deaths: 609,820[69]
Verified
10The WHO reports that 60% of people who need cancer treatment in low- and middle-income countries do not receive it[15]
Single source
11WHO reports that access to pain relief is inadequate for millions, including those with cancer[15]
Verified
12WHO reports that in many countries, cancer screening coverage is low[64]
Verified
13The Global Cancer Observatory (IARC) provides cancer incidence and mortality by country[70]
Verified
14IARC GLOBOCAN provides cancer burden estimates for 185 countries[71]
Verified
15The Global Cancer Observatory includes data for 36 cancer sites[71]
Single source
16WHO Global Health Observatory reports radiotherapy access gaps; in 2019, around 50% of populations in low-income countries did not have access to radiotherapy[72]
Single source
17IAEA estimates global radiotherapy needs: additional 5,000 machines needed to meet demand (commonly cited)[73]
Single source
18A Lancet Oncology commission found that 30% of cancer patients in LMICs do not have access to diagnosis[74]
Verified
19A Lancet Oncology article reported that only 35% of cancer patients in low-income settings receive timely cancer treatment[75]
Verified
20The US Cancer Statistics (USCS) data include statewide cancer incidence, survival, and mortality[76]
Verified
21CDC’s USCS provides data for all 50 states and DC[77]
Verified
22CDC reports that cancer is the second leading cause of death in the US[78]
Verified
23NIH NCI notes that clinical trials can improve access to new treatments[79]
Directional
24NCI reports that only about 5% of adults with cancer enroll in clinical trials[80]
Single source
25ASCO states that delays in cancer treatment can worsen outcomes, highlighting access gaps[81]
Verified
26The National Cancer Institute states that disparities in cancer outcomes exist by race and socioeconomic status[82]
Verified
Health System, Economics, Access, and Equity Interpretation
Cancer care in the United States can cost more than $100,000 a year for some patients, yet millions around the world still cannot get the basics, including timely diagnosis, treatment, pain relief, screening, and even radiotherapy, while the gap between the number of people newly diagnosed and those who die keeps widening and access to newer therapies remains limited even at home.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Cancer Treatment Statistics. Gitnux. https://gitnux.org/cancer-treatment-statistics
MLA
Min-ji Park. "Cancer Treatment Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/cancer-treatment-statistics.
Chicago
Min-ji Park. 2026. "Cancer Treatment Statistics." Gitnux. https://gitnux.org/cancer-treatment-statistics.
References
- 1gco.iarc.fr/today/fact-sheets-cancers?advisory=0&age=15-85&sex=0&cancer=39&country=0&pop=0&loc=0&y=2021
- 2gco.iarc.fr/today/fact-sheets-cancers?cancer=8&type=0&sex=0
- 3gco.iarc.fr/today/fact-sheets-cancers?cancer=1&type=0&sex=0
- 4gco.iarc.fr/today/fact-sheets-cancers?cancer=6&type=0&sex=0
- 5gco.iarc.fr/today/fact-sheets-cancers?cancer=10&type=0&sex=0
- 6gco.iarc.fr/today/fact-sheets-cancers?cancer=20&type=0&sex=0
- 7gco.iarc.fr/today/fact-sheets-cancers?cancer=17&type=0&sex=0
- 8gco.iarc.fr/today/fact-sheets-cancers?cancer=12&type=0&sex=0
- 9gco.iarc.fr/today/fact-sheets-cancers?cancer=15&type=0&sex=0
- 10gco.iarc.fr/today/fact-sheets-cancers?cancer=18&type=0&sex=0
- 11gco.iarc.fr/today/fact-sheets-cancers?cancer=14&type=0&sex=0
- 12gco.iarc.fr/today/fact-sheets-cancers?cancer=25&type=0&sex=0
- 13gco.iarc.fr/today/fact-sheets-cancers?cancer=39&type=0&sex=0
- 14gco.iarc.fr/today/fact-sheets-populations?type=0&population=900&y=2018
- 17gco.iarc.fr/today/fact-sheets-cancers?cancer=39&type=0&sex=1
- 18gco.iarc.fr/today/fact-sheets-cancers?cancer=39&type=0&sex=2
- 70gco.iarc.fr/today
- 71gco.iarc.fr/today/about-gco
- 15who.int/news-room/fact-sheets/detail/cancer
- 42who.int/publications/i/item/9789241562212
- 57who.int/teams/immunization-vaccines-and-biologicals/strategies/engagement/who-recommendations-for-hpv-vaccines
- 58who.int/news-room/fact-sheets/detail/hepatitis-b
- 64who.int/publications/i/item/9789241547687
- 72who.int/publications/i/item/9789240000318
- 16seer.cancer.gov/statfacts/html/cancer.html
- 19seer.cancer.gov/statfacts/html/breast.html
- 20seer.cancer.gov/statfacts/html/lungb.html
- 21seer.cancer.gov/statfacts/html/colorectal.html
- 22seer.cancer.gov/statfacts/html/prostat.html
- 23seer.cancer.gov/statfacts/html/bladder.html
- 24seer.cancer.gov/statfacts/html/kidrp.html
- 25seer.cancer.gov/statfacts/html/melanoma.html
- 26seer.cancer.gov/statfacts/html/nhl.html
- 27seer.cancer.gov/statfacts/html/hodgkin.html
- 28seer.cancer.gov/statfacts/html/leuks.html
- 29seer.cancer.gov/statfacts/html/thyroid.html
- 30seer.cancer.gov/statfacts/html/pancreas.html
- 31seer.cancer.gov/statfacts/html/corp.html
- 32seer.cancer.gov/statfacts/html/ovary.html
- 33seer.cancer.gov/statfacts/html/livb.html
- 34seer.cancer.gov/statfacts/html/stomach.html
- 35seer.cancer.gov/statfacts/html/esophagus.html
- 36seer.cancer.gov/statfacts/html/headneck.html
- 37seer.cancer.gov/statfacts/html/mulmyel.html
- 38seer.cancer.gov/statfacts/html/larynx.html
- 48seer.cancer.gov/data/seer-treatment.html
- 39cancer.gov/about-cancer/childhood/childhood-cancer-facts
- 40cancer.gov/types/childhood-cancers/childhood-treatment-pdq
- 41cancer.gov/about-cancer/treatment/types/radiation-therapy
- 43cancer.gov/about-cancer/treatment/immunotherapy
- 44cancer.gov/about-cancer/treatment/targeted-therapies
- 45cancer.gov/about-cancer/treatment/hormone-therapy
- 46cancer.gov/about-cancer/treatment/clinical-trials
- 49cancer.gov/about-cancer/treatment/types/neoadjuvant-therapy
- 50cancer.gov/about-cancer/treatment/types/adjuvant-therapy
- 51cancer.gov/about-cancer/treatment/types/stem-cell-transplant
- 52cancer.gov/about-cancer/treatment/immunotherapy/car-t-cells-fact-sheet
- 66cancer.gov/about-cancer/impact-of-cancer/medicare-spending
- 79cancer.gov/about-cancer/treatment/clinical-trials/who-can-take-part
- 80cancer.gov/about-cancer/treatment/clinical-trials/what-is-a-clinical-trial
- 82cancer.gov/about-cancer/causes-prevention/race-disparities
- 47fda.gov/drugs/therapeutic-area-guidances
- 53nccn.org/patients/guidelines/content/PDF/cns-patient.pdf
- 54cancer.org/treatment.html
- 67cancer.org/research/cancer-facts-statistics/cancer-amounts.html
- 68cancer.org/research/cancer-facts-statistics/cancer-facts-figures/2022-cancer-facts-figures.html
- 69cancer.org/research/cancer-facts-statistics/cancer-facts-figures/2023-cancer-facts-figures.html
- 55cdc.gov/cancer/hpv/basic_info/index.htm
- 56cdc.gov/cancer/hpv/basic_info/learn_more.htm
- 59cdc.gov/hepatitis/hbv/index.htm
- 77cdc.gov/cancer/uscs/about/index.htm
- 78cdc.gov/cancer/dcpc/data-and-statistics/index.htm
- 60uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
- 61uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening
- 62uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
- 63uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening
- 65healthcostinstitute.org/wp-content/uploads/2018/06/Health-Cost-Institute-Cancer-Costs.pdf
- 73iaea.org/newscenter/news/radiotherapy-strategy
- 74thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30111-1/fulltext
- 75thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30066-8/fulltext
- 76gis.cdc.gov/Cancer/USCS/#/AtAGlance/
- 81asco.org/research-guidelines/cancer-care-guidelines